Rahul Shenolikar

Rahul Shenolikar is a seasoned professional in the field of oncology outcomes research, currently serving as the Lung Cancer Lead and Global Real World Evidence Strategy Lead at AstraZeneca since September 2015. In this role, Rahul oversees the Global RWE Strategy for key lung cancer therapies, including Imfinzi, Tagrisso, and Enhertu. Prior to this, Rahul held the position of Director of US Health Economics Outcomes Research, focusing on Health Economics and Outcomes Research (HEOR) strategies for various oncology franchises, such as Women's Cancer and Immuno-Oncology. Rahul's experience includes significant roles at GlaxoSmithkline from October 2006 to September 2015, where responsibilities ranged from managing US Health Outcomes/Epidemiology for vaccines to leading Comparative Effectiveness Research and Health Policy Research. Academic credentials include a PhD in Pharmacoeconomics from The Ohio State University and a Master of Science in Pharmacy Administration from The University of Toledo.